Hector Castro (Colombia), 2018-21

Hector Castro is a Doctor in Medicine and Surgery. He has an MSc in Health Policy, Planning and Financing, from the London School of Hygiene & Tropical Medicine (LSHTM) and a joint degree with the London School of Economics & Political Science (LSE). He specialized in Health Management and had a previous MSc in Occupational Health (Public Health Branch). He is a Doctor in Public Health and Policy/Health Economics from the University of London (LSHTM), and former Takemi Postdoctoral Fellow at the T.H. Chan Harvard School of Public Health.

Dr. Castro has over 18 years of broad professional experience, as Chief Officer, Technical Advisor, Director and Manager in strategic planning, quality assurance, health, safety and environment for pharmaceutical, health insurance and non-governmental organizations. His main focus of work has been on health systems` strengthening in areas such as quality assurance, assessment, strategic purchasing and provision of healthcare technologies (including medicines, devices and procedures).

Dr. Castro has more than ten years of experience as an international consultant in health care access, health economics, health policy, priority setting, health technology assessment (HTA) and health systems´ reform. He is also familiar with and has relevant experience in health systems and markets in low and middle-income countries (LMICs).  His previous working experience includes the US, United Kingdom, Colombia, Ecuador, Ukraine, Belarus, Thailand, Peru, Costa Rica, Brazil, Mexico, Chile, Turkey and Tunisia. He also has experience as a researcher and lecturer for undergraduate and post graduate students in ivy league institutions in Latin America, the US and United Kingdom.

Dr. Castro is a former funding Chief Executive Director of the HTA Institute of Colombia (IETS) and Director of Medicines and Technologies at the Ministry of Health and Social Protection of Colombia. Currently, he is Senior Technical Director of Pharmaceutical Economics and Financing at MSH. Starting June 2018 and until 2021, he will serve at the Board of Directors of the Health Technology Assessment International (HTAi), one of the most prominent international networks in the field of HTA.

Catherine Holliday (Australia), 2019-22

Catherine Holliday is Chief Executive of the Centre for Community-Driven Research (CCDR), a non- profit organisation driving a more person-centred health sector. Catherine’s professional work has focused on developing solutions to health system challenges and she has been actively involved in developing more equitable and systematic approaches to community engagement in HTA and all parts of the health system. At CCDR, Catherine is leading the development of a global repository of patient experience data, global patient organisation networks, and piloting various ways for patients to better engage in decision-making and increase their access to treatments and services.

Catherine has significant experience working with government, industry, not- for-profit organisations as well as research and international organisations including working in Geneva, Switzerland with the Australian Department of Foreign Affairs and Trade, the International Organisation for Migration, UNICEF and the GAVI Alliance. She has also worked as a nurse and researcher in Australia and the USA with roles including Head of Research at Cancer Council NSW Australia and Head of Policy and Strategy at the Kinghorn Cancer Centre (Sydney, Australia).

Catherine holds a Bachelor of Nursing degree, a graduate diploma in nutrition, a Masters in Health Promotion, a Masters in Health Science and her PhD thesis investigated the relationship between the global, social and economic drivers of research and how to translate results into policy, practice and population health.

Wim Goettsch (Netherlands), 2019-22

Wim Goettsch, PhD is currently Special Advisor HTA at the Dutch National Health Care Institute. He was the Director of the EUnetHTA JA3 (2016-2020) Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. Since 2019, he has held a position as an Associate Professor at Utrecht University (NL), where he is leading a new H2020 consortium called HTx, New Methods for Health Technology Assessment (2019-2024) with fifteen partners around Europe. Between 2010 and 2015, he was the Project Leader of Work Package 5 of EUnetHTA Joint Action 1 & 2, in which rapid joint assessments of relative effectiveness of pharmaceuticals were piloted between more than 25 HTA organisations around Europe. Between 2010 and 2013, he was the Deputy Secretary of the Medicinal Products Reimbursement Committee at Dutch National Health Care Institute. He is currently a member of the HTAi Policy Forum Committee and has been Director in the Board (2013-2015) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Before joining the National Health Care Institute, he worked as a research manager for the PHARMO Institute and was responsible for the coordination of numerous pharmacoepidemiological and outcomes studies for international offices of pharmaceutical companies such as AstraZeneca, Novartis, Pfizer and GSK. He also worked as a senior epidemiologist in the field of antimicrobial resistance for the National Institute for Public Health and the Environment in the Netherlands and was involved in the initiation of the European Antimicrobial Resistance Surveillance Network (EARS-Net) that is now coordinated by the ECDC. He was also seconded as a scientific secretary for Dutch National Health Council on the topic of antimicrobial growth promotors in animal feed (1997-1998). He has a PhD in immunology and an advanced education in pharmaco- epidemiology and pharmaco-economics. He has more than 70 publications in peer-reviewed international journals.

Karen Facey (United Kingdom), 2017-20

Karen Facey is a Chartered Statistician, Honorary Member of the Faculty of Public Health, and Fellow of the Royal Society of Medicine. Following a statistical career in the pharmaceutical industry and medicines regulation, Karen was founding Chief Executive of the first national Health Technology Assessment (HTA) Agency in Scotland, which established the Scottish Medicines Consortium. She now works internationally as a consultant with all stakeholders, advising on matters relating to HTA and patient involvement, with a particular interest in Managed Entry Agreements and rare diseases.

During her consultancy, Karen has served for eight years as a Non-Executive Director on the governance board of a regional healthcare payer/provider in Scotland. For eleven years, she led government committees revising the funding formulae for NHSScotland resource allocation. She was Chair of the HTAi Global Policy Forum for three years. In 2014, she was named by the British Science Council as one of the top 100 practicing scientists in the UK for her work in HTA and patient wellbeing.

Karen is now a member of the Scottish Health Technologies Group, which provides national appraisal advice on non-medicine technologies. She is an Honorary Research Fellow at the Usher Institute of Population Health Sciences and Informatics at the University of Edinburgh, where she is involved in research related to the use of administrative health data to optimize medicine usage.

Karen has been committed to HTAi since its inception. She was on the founding board of HTAi and established the HTAi Interest Groups for Patient and Citizen Involvement in HTA (PCIG) and Assessment of Vaccination Programmes. She was Chair of the HTAi Policy Forum from 2008-2010 and has served as its scientific secretary. She was Co-Chair of the International Scientific Programme Committee for the conference in South Korea. She has represented HTAi on various collaborative efforts with patient groups, including EUPATI, EURORDIS symposium and ISPOR roundtable. Karen is on the editorial board of several journals including IJTAHC and has led themed editions with the HTAi PCIG. She was invited by Springer to develop a book about Patient Involvement in HTA with members of PCIG and this will be published in summer 2017.

Karen sits on the HTAi Policy Forum Coordinating Committee and the Interest Group steering committee.

Rabia Kahveci (Ukraine), 2017-20

Professor Rabia Kahveci is Senior Technical Advisor for Pharmaceutical Policy and Governance of SAFEMed, a USAID funded, MSH led project that aims to support development of evidence-based pharmaceutical policies and HTA in Ukraine. She has been a Director of HTAi since 2013, the Chair of HTAi Developing Countries Interest Group until 2019, the Chair of Annual Meeting Committee, and the Chair of newly-established Medical Devices Interest Group starting from 2019. She also chairs the Eurasian HTA Initiative with institutional members from 9 countries. Prior to her position in SAFEMed, she was the Director of a Hospital-based HTA Center in Turkey that covered HTA, innovation for medical devices and real world evidence. In Turkey, she also served as a member of the Pharmaceuticals Reimbursement Committee of the Turkish Social Security Institution during transition to universal health coverage and was one of the co-authors of the reimbursement guidelines; the National Clinical Quality Coordinator of the Turkish Ministry of Health (MoH), with the coordinating task of all activities around HTA, clinical guidelines, quality and performance-based payment; and the President of Turkish Evidence-Based Medicine Society. She is a family physician by background with additional trainings in Italy, Spain, Canada, and the USA. In addition to her advisory roles to Turkish Health Care Institutes, the Turkish MoH and several national and international NGOs, she is also recognized as an editor of eight books and the author of more than 150 articles.

Debjani (Jani) Mueller (South Africa), 2019-22

Debjani (Jani) Mueller, MEng is a Senior Researcher at Charlotte Maxeke Medical Research Cluster (CMeRC) in Johannesburg. She currently holds a faculty position with University of Pretoria in South Africa and is a doctoral candidate at the Technical University of Berlin.

Over the last decade, she has gained practical experience in evaluating medical devices as part of her work with the CMeRC team and shared her experience through training throughout South Africa and other parts of the world through distance-based education. She has taught hospital managers in South Africa (MPH in Hospital management) as an initiative of the EU and South African Department of Health.

Her research focuses on advancing the methods used in the area of medical device assessment to enhance its usefulness in the context of real-world decision-making which involves taking a life-cycle approach to medical technology assessment.

Jani continues to focus her effort on promotion, collaboration and raising awareness of sustainable HTA development and implementation. She was a founding member of South African HTA Society (SAHTAS), has been a director on the INAHTA Board since 2013, and is currently the chair of the HTAi Interest Group on developing Countries. She has served on the International Scientific Program Committee of HTAi’s Annual Meeting over the years and more recently is an Associate Editor of IJTAHC. Furthermore, she has been co-opted as a Board member by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) South Africa Chapter Board for the term 2018-2019.

Jani nurtures a keen interest in building competencies and education and training in HTA, especially in emerging settings. She has published and co-authored a number of articles, contributed to book chapters and presented her research findings to an array of scientific audiences.

Leonor Varela-Lema (Spain), 2019-22

Leonor Varela-Lema is BSc, PhD in Pharmacy and holds a Master’s Degree in Preventive Medicine and Public Health from the University of Santiago de Compostela (Spain). She has a 16 years background in health technology assessment and health care research, with recognized experience at the national and international level. Currently, she is the International Project Manager of the Health Technology Assessment Department (avalia-t) of the Galician Agency for Health Knowledge Management (ACIS).

During her career, she has coordinated important initiatives in the field of HTA, including the development of the Spanish NHS guideline that establishes the structured methodological framework for the implementation of post-introduction observational studies to support decision making and the development of the topic prioritisation and selection strategy. She has been involved in EUnetHTA since its inception (EUnetHTA Project (2006-2008), participating in the development of the first version of the “Core-Model” and other key documents, like the position paper on how to best formulate research recommendations for primary research arising from HTA. In the ongoing Joint Action 3 (2016-2020), she is leading two activity centre departments, which focus on HTA Joint Production and generation of cross border post-launch evidence for medical devices. She has participated in the EU funded SEED Consortium (Shaping Early Dialogues for Health Technologies) (2014-2015) and is currently part of non-pharma EUnetHTA early dialogues Working Group.

She has been an active member of HTAi since 2005. She has been a member of the Interest Groups on HTAi Disinvestment & Early Awareness and Regulatory interactions & Conditional coverage, and is a member of the HTA glossary Steering Committee, which supports the development of the HTA glossary, which is a collaboration of INAHTA and HTAi.

Leonor Varela-Lema has lectured extensively on HTA and has published more than 100 papers concerning related topics. She is as an evaluator of projects funded by the Funds for Health Research of the Spanish Ministry of Health and the Regional Government of Andalucía.  Her main areas of expertise are: epidemiology, public health, HTA, health care service research and reimbursement policy making of medical devices and other non pharma technologies.

Past President Sean Tunis (United States), 2019-21

Sean Tunis, MD, MSc, is the Founder, President and Chief Executive Officer of the Center for Medical Technology Policy (CMTP) in Baltimore, Maryland. CMTP is an independent, non-profit organization that provides a neutral platform for multi-stakeholder collaborations that are focused on improving the quality, relevance and efficiency of clinical research. His work currently focuses on expanding infrastructure for the conduct of pragmatic clinical trials within the health care delivery systems, developing condition-specific evidentiary standards for reimbursement, and promoting greater engagement of patients and consumers in clinical research. Tunis serves on the Board of HTAi, the Health Sciences Policy Council for ISPOR and a number of other advisory boards for public and private sector organizations focused on issues of comparative effectiveness, innovation, health technology assessment, evidence-based medicine, clinical research and reimbursement.